SAB Biotherapeutics has spent the year converting a cattle-based antibody platform into a funded, single-asset race inside autoimmune type one diabetes, and the second-quarter print is the first clean look at that conversion after the Sanofi-backed recapitalization. The company is no longer arguing that a living production system can make fully human polyclonal immunoglobulin. It is arguing that the lead human anti-thymocyte globulin can preserve remaining insulin-producing beta cells in newly diagnosed Stage Three disease, on a two-day infusion schedule, in a wider age and diagnosis window than the incumbent monoclonal. Sanofi now sits on both sides of that argument: as a PIPE investor from last summer and as the marketer of Tzield, which received accelerated approval in June for children and adolescents recently diagnosed with Stage Three disease. That approval did SAB a favor it cannot fully control. It validated C-peptide as a registrational surrogate, and it also put a commercial product into the same clinic calendar SAB is trying to fill.
The financial tension is not insolvency. Cash, cash equivalents, and investment securities totaled $208 million at mid-year, and management states that runway reaches through calendar two thousand twenty-eight. What changed in the quarter is the cost of acting like a company that intends to finish a registrational study, open a second farm, and start pre-commercial work at the same time. Research and development more than doubled versus the year-ago quarter as SAFEGUARD sites came online. General and administrative expense rose even faster on headcount and stock-based pay. Operating cash use for the first half was still modest against the securities book, which is why the equity can trade near cash and still look funded. The offset sits in the capital structure rather than the income statement. Milestone warrants from the July private placement and a stack of convertible preferred can more than double the share count if the clinical story works.
The operating evidence from the quarter is enrollment, not efficacy. More than sixty SAFEGUARD sites are active across the United States, Australia, New Zealand, the United Kingdom, and the European Union, Part A in twelve adults is complete, and Part B is recruiting toward a year-end finish with topline guided for the second half of next year. Breakthrough T1D awarded a grant to an investigator-led Phase Three that would test the same molecule out to two years from diagnosis, which is how SAB tries to turn a narrow new-onset label into a broader residual-beta-cell franchise. The Phase One T1D cohort that underpins the enthusiasm remains four treated adults. Whether sixty sites can finish a one-hundred-fifty-nine-patient pediatric-heavy study on time, without diluting the C-peptide window the Food and Drug Administration has now blessed, is the question the next two quarters have to answer.